Literature DB >> 20185275

Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.

Takashi Niwa1, Yoshinori Imanishi, Tomofumi Ohmori, Katsuhiko Matsuura, Nobuo Murakami, Yoshinori Itoh.   

Abstract

An initial loading dose of teicoplanin is required to reach the optimal trough concentration (> or = 10 microg/mL) rapidly. To attain the optimal teicoplanin concentration efficiently, an individual loading dose regimen based on population pharmacokinetics, in which the target trough concentration was set to 15 microg/mL, was defined. Among 70 patients, 33 patients received the individual loading dose regimen, 33 patients received the conventional loading dose regimen (200mg or 400mg every 12h on Day 1 followed by 200mg once daily) and 4 patients received no loading dose. The proportion of patients showing an optimal plasma concentration was 88% in the individual loading dose regimen but only 33% in the conventional loading dose regimen. No patient without a loading dose showed the optimal concentration. Both total loading dose and plasma concentration were significantly (P<0.001) higher in the individual loading dose group than in the conventional loading dose group. Notably, the trough concentration was almost constant in patients with individual loading doses ranging from 800 mg to 1800 mg. These findings suggest that individual adjustment of the initial loading dose of teicoplanin is potentially useful to attain the optimal concentration rapidly. Copyright 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185275     DOI: 10.1016/j.ijantimicag.2009.12.018

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.

Authors:  Catherine J Byrne; Jason A Roberts; Brett McWhinney; Jerome P Fennell; Philomena O'Byrne; Evelyn Deasy; Sean Egan; Ronan Desmond; Helen Enright; Sheila A Ryder; Deirdre M D'Arcy; Johnny McHugh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

2.  Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.

Authors:  Jin Wi; Hayeon Noh; Kyoung Lok Min; Seungwon Yang; Byung Hak Jin; Jongsung Hahn; Soo Kyung Bae; Jiseon Kim; Min Soo Park; Donghoon Choi; Min Jung Chang
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  Therapeutic drug concentrations of teicoplanin in clinical settings.

Authors:  So-Yun Nah; Jae Hyoung Im; Jin Yeob Yeo; Ji-Hyeon Baek; Cheol-Woo Kim; Moon-Seok Nam; Hye-Kyung Lee; Moon-Hyun Chung; Jin-Soo Lee
Journal:  Infect Chemother       Date:  2014-03-21

4.  Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yuki Hanai; Yoshiko Takahashi; Takashi Niwa; Toshihiko Mayumi; Yukihiro Hamada; Toshimi Kimura; Kazuaki Matsumoto; Satoshi Fujii; Yoshio Takesue
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

5.  Population Pharmacokinetics and Dosage Optimization of Teicoplanin in Children With Different Renal Functions.

Authors:  Liuliu Gao; Hua Xu; Qi Ye; Sichan Li; Jun Wang; Yan Mei; Changhe Niu; Ting Kang; Chen Chen; Yang Wang
Journal:  Front Pharmacol       Date:  2020-05-05       Impact factor: 5.810

6.  Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.

Authors:  V Ramos-Martín; M N Neely; K Padmore; M Peak; M W Beresford; M A Turner; S Paulus; J López-Herce; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.